THERAPEUTIC IMPLICATIONS OF TARGETED SEQUENCING AND miRNA-SEQ OF B CELL LYMPHOMAS

Esra Esmeray SÖNMEZ; Tevfik HATİPOĞLU; Xiaozhou HU; Hongling YUAN; Ayça ERŞEN DANYELİ; Ayla ANAR ARICI; Ahmet ŞEYHANLI; Zühal ÖNDER SİVİŞ; Bengü DEMİRAĞ; Eda ATASEVEN; Dilek İNCE; Zekiye ALTUN; Safiye AKTAŞ; İnci ALACACIOĞLU; Tuğba SÜZEK; Nazan ÖZSAN; Taner Kemal ERDAĞ; Elvan Caglar CİTAK; Sermin ÖZKAL; Mehmet Ali ÖZCAN; Nazan ÇETİNGÜL; Erdener ÖZER; Tezer KUTLUK; Nur OLGUN; Can KÜÇÜK

doi:https://doi.org/10.26650/JARHS2021-1138755

Article Details

THERAPEUTIC IMPLICATIONS OF TARGETED SEQUENCING AND miRNA-SEQ OF B CELL LYMPHOMAS

Authors:

Esra Esmeray SÖNMEZ | Tevfik HATİPOĞLU | Xiaozhou HU | Hongling YUAN | Ayça ERŞEN DANYELİ | Ayla ANAR ARICI | Ahmet ŞEYHANLI | Zühal ÖNDER SİVİŞ | Bengü DEMİRAĞ | Eda ATASEVEN | Dilek İNCE | Zekiye ALTUN | Safiye AKTAŞ | İnci ALACACIOĞLU | Tuğba SÜZEK | Nazan ÖZSAN | Taner Kemal ERDAĞ | Elvan Caglar CİTAK | Sermin ÖZKAL | Mehmet Ali ÖZCAN | Nazan ÇETİNGÜL | Erdener ÖZER | Tezer KUTLUK | Nur OLGUN | Can KÜÇÜK

Publisher:

Istanbul University

Main Topics:

Astronomy and allied sciences | Diseases

Journal:

Journal of Advanced Research in Health Sciences 2022 Vol.5 Issue S-1, pp.31-31

Document Type:

Article

Publication Date:

8/2022

Document Language:

English

Document ID (Org No.):

2000615826

Frequency:

Tri-annual

eISSN:

2651-4060

DOI:

https://doi.org/10.26650/JARHS2021-1138755

Abstract:

 

Objective: Next-generation sequencing (NGS)-based approaches facilitated the identification of genomic and transcriptomic alterations associated with
the development of B-cell lymphomas. Identification of these aberrancies during diagnosis may be helpful in choosing the most appropriate targeted
therapy. Follicular lymphoma and Burkitt lymphoma are B-cell non-Hodgkin lymphomas with the potential to benefit from molecular targeted therapy.
Materials and Methods: Targeted sequencing or miRNA-Seq were performed on FFPE tumor tissues of FL and pediatric BL (pBL) cases, respectively, using
the HiSeq system. Cancer- associated somatic mutations were identified in FL tumor tissue DNA samples through a computational bioinformatics pipeline.
miRNAs overexpressed in pBL cases compared with the tonsil centroblasts of non-cancer control cases were identified through differential expression
analyses. Sanger sequencing or qRT-PCR were used to cross-validate targeted NGS and miRNA-Seq results, respectively. The literature search was
performed to evaluate the therapeutic potential of these somatic mutations and upregulated miRNAs.
Results: Targeted sequencing of FL tumor tissues revealed activating mutations in genes of biological processes or oncogenic signaling pathways. Several
miRNAs were identified to be significantly overexpressed in pBL cases. The literature search revealed that targeted therapeutic approaches may be
available for the FL or pBL patients with the identified mutations or upregulated miRNAs in tumor tissues.
Conclusion: Targeted NGS may be applied during diagnosis to choose appropriate therapy for FL patients. Upregulated miRNAs provide unique
opportunities for personalized targeted therapy of pBL patients.

 

Objective: Next-generation sequencing (NGS)-based approaches facilitated the identification of genomic and transcriptomic alterations associated with
the development of B-cell lymphomas. Identification of these aberrancies during diagnosis may be helpful in choosing the most appropriate targeted
therapy. Follicular lymphoma and Burkitt lymphoma are B-cell non-Hodgkin lymphomas with the potential to benefit from molecular targeted therapy.
Materials and Methods: Targeted sequencing or miRNA-Seq were performed on FFPE tumor tissues of FL and pediatric BL (pBL) cases, respectively, using
the HiSeq system. Cancer- associated somatic mutations were identified in FL tumor tissue DNA samples through a computational bioinformatics pipeline.
miRNAs overexpressed in pBL cases compared with the tonsil centroblasts of non-cancer control cases were identified through differential expression
analyses. Sanger sequencing or qRT-PCR were used to cross-validate targeted NGS and miRNA-Seq results, respectively. The literature search was
performed to evaluate the therapeutic potential of these somatic mutations and upregulated miRNAs.
Results: Targeted sequencing of FL tumor tissues revealed activating mutations in genes of biological processes or oncogenic signaling pathways. Several
miRNAs were identified to be significantly overexpressed in pBL cases. The literature search revealed that targeted therapeutic approaches may be
available for the FL or pBL patients with the identified mutations or upregulated miRNAs in tumor tissues.
Conclusion: Targeted NGS may be applied during diagnosis to choose appropriate therapy for FL patients. Upregulated miRNAs provide unique
opportunities for personalized targeted therapy of pBL patients.

Article Details

THERAPEUTIC IMPLICATIONS OF TARGETED SEQUENCING AND miRNA-SEQ OF B CELL LYMPHOMAS

Publisher: Istanbul University

Main Topics: Astronomy and allied sciences | Diseases

Journal: Journal of Advanced Research in Health Sciences 2022 Vol.5 Issue S-1, pp.31-31

Document Type: Article

Publication Date: 8/2022

Document Language: English

Document ID (Org No.): 2000615826

Frequency: Tri-annual

eISSN: 2651-4060

DOI: https://doi.org/10.26650/JARHS2021-1138755

Issues

Publisher:

Istanbul University

Main Topics:

Astronomy and allied sciences | Diseases

Journal:

Journal of Advanced Research in Health Sciences 2022 Vol.5 Issue S-1, pp.31-31

Document Type:

Article

Publication Date:

8/2022

Document Language:

English

Document ID (Org No.):

2000615826

Frequency:

Tri-annual

eISSN:

2651-4060

DOI:

https://doi.org/10.26650/JARHS2021-1138755